Revitalizing Japan's biomedical ecosystem: Policy initiatives, challenges, and future directions.
Ryo Okuyama
Drug Discoveries & Therapeutics, 19, 4, 214-219, 2025
Leveraging Corporate Assets and Talent to Attract Investors in Japan: A Country with an Innovation System Centered on Large Companies.
Ryo Okuyama
Journal of Risk and Financial Management, 17, 12, 539-, 2024
Developer and Partnership Differences in COVID-19 and Other Infections: Insights from DNA Vaccines.
Ryo Okuyama
Journal of Market Access & Health Policy, 12, 4, 317-325, 2024
アカデミアの創薬への貢献：日本の現状と展望
奥山亮
Translational and Regulatory Sciences(日本語翻訳版), -, 2023
Chronological Analysis of First-in-Class Drugs Approved from 2011 to 2022: Their Technological Trend and Origin.
Ryo Okuyama
Pharmaceutics, 15, 7, 1794-, 2023
Importance of drug target selection capability for new drug innovation: definition, fostering process and interaction with organizational management.
Okuyama R, Tsujimoto M
Prometheus, 36, 2, 135-152, 2020
創薬における「創薬標的選定能力」―革新的新薬創製の競争優位に寄与する新しい能力概念とその成因―
奥山亮, 辻本将晴
イノベーション・マネジメント, 17, 141-156, 2020
激変する新薬開発の最前線 主戦場はバイオベンチャーへ
奥山亮
医療白書2019年度版, 30-35, 2019
企業側からみたスター・サイエンティストとの協働と可能性：医薬品産業のケース
奥山亮
研究技術計画, 34, 2, 129-138, 2019
アカデミア創薬の課題－創薬応用研究部分の能力に関する分析－
奥山亮, 辻本将晴
医療と社会, 27, 2, 237-250, 2017
アカデミア創薬の背景と現状 -産学官各々の立場からの分析-
奥山亮, 辻本将晴
産学連携学, 13, 2, 127-134, 2017
Importance of tacit knowledge in incremental innovation: Implications from drug discovery cases
Okuyama R
Journal of Strategy and Management, 10, 1, 118-130, 2017
The types of scientific information and technologies acquired from university-industry relationships in the Japanese pharmaceutical industry - An empirical study from 1980 to 2012
Okuyama R
International Journal of Technology Transfer and Commercialisation, 13, 3/4, 178-191, 2015
Acquisition of drug candidates in New Drug Development in Japan
Okuyama R, Osada H
Proceedings of Portland International Center for Management of Engineering and Technology, -, 2014
University-Industry Collaboration in Drug Discovery in Japan: An Empirical Analysis over Thirty Years
Okuyama R, Osada H
Proceedings of Portland International Center for Management of Engineering and Technology, -, 2013
Potent and Orally Bioavailable GPR142 Agonists as Novel Insulin Secretagogues for the Treatment of Type 2 Diabetes
Toda N, Hao X, Ogawa Y, Oda K, Yu M, Fu Z, Chen Y, Kim Y, Lizarzaburu M, Lively S, Lawlis S, Murakoshi M, Nara F, Watanabe N, Reagan JD, Tian H, Fu A, Motani A, Liu Q, Lin YJ, Zhuang R, Xiong Y, Fan P, Medina J, Li L, Izumi M, Okuyama R, Shibuya S.
ACS Med Chem Lett., 4, 8, 790-794, 2013
Aminopyrazole–Phenylalanine Based GPR142 Agonists: Discovery of Tool Compound and in Vivo Efficacy Studies
Yu M, Lizarzaburu M, Motani A, Fu Z, Du X, Liu J, Jiao X, Lai SJ, Fan P, Fu A, Liu Q, Murakoshi M, Nara F, Oda K, Okuyama R, Reagan JD, Watanabe N, Yamazaki M, Xiong Y, Zhang Y, Zhuang R, Lin DC, Houze J, Medina JC, Li L.
ACS Med. Chem. Lett., 4, 9, 829-834, 2013
Phenylalanine Derivatives as GPR142 Agonists for the Treatment of Type II Diabetes
Du X, Kim YJ, Lai S, Chen X, Lizarzaburu M, Turcotte S, Fu Z, Liu Q, Zhang Y, Motani A, Oda K, Okuyama R, Nara F, Murakoshi M, Fu A, Reagan JD, Fan P, Xiong Y, Shen W, Li L, Houze J, Medina JC.
Bioorg Med Chem Lett., 22, 19, 6218-6223, 2012
Discovery and optimization of a novel series of GPR142 agonists for the treatment of type 2 diabetes mellitus
Lizarzaburu M, Turcotte S, Du X, Duquette J, Fu A, Houze J, Li L, Liu J, Murakoshi M, Oda K, Okuyama R, Nara F, Reagan J, Yu M, Medina JC.
Bioorg Med Chem Lett., 22, 18, 5942-5947, 2012
Pharmacology and in Vitro Profiling of a Novel Peroxisome Proliferator-Activated Receptor γ Ligand, Cerco-A.
Wakabayashi K, Hayashi S, Matsui Y, Matsumoto T, Furukawa A, Kuroha M, Tanaka N, Inaba T, Kanda S, Tanaka J, Okuyama R, Wakimoto S, Ogata T, Araki K, Ohsumi J.
Biol Pharm Bull., 34, 7, 1094-1104, 2011
Novel benzoylpiperidine-based stearoyl-CoA desaturase-1 inhibitors: Identification of 6-[4-(2-methylbenzoyl)piperidin-1-yl]pyridazine-3-carboxylic acid (2-hydroxy-2- pyridin-3-ylethyl)amide and its plasma triglyceride-lowering effects in Zucker fatty rats.
Uto Y, Ogata T, Kiyotsuka Y, Ueno Y, Miyazawa Y, Kurata H, Deguchi T, Watanabe N, Konishi M, Okuyama R, Kurikawa N, Takagi T, Wakimoto S, Ohsumi J.
Bioorg Med Chem Lett., 20, 1, 341-345, 2009
Novel and potent inhibitors of stearoyl-CoA desaturase-1. Part II: Identification of 4-ethylamino-3-(2-hydroxyethoxy)-N-[5-(3-trifluoromethylbenzyl) thiazol-2-yl]benzamide and its biological evaluation
Uto Y, Ogata T, Kiyotsuka Y, Miyazawa Y, Ueno Y, Kurata H, Deguchi T, Yamada M, Watanabe N, Takagi T, Wakimoto S, Okuyama R, Konishi M, Kurikawa N, Kono K, Osumi J.
Bioorg Med Chem Lett., 19, 15, 4159-4166, 2009
Novel and potent inhibitors of stearoyl-CoA desaturase-1. Part I: Discovery of 3-(2-hydroxyethoxy)-4-methoxy-N-[5-(3-trifluoromethylbenzyl)thiazol -2-yl]benzamide
Uto Y, Ogata T, Harada J, Kiyotsuka Y, Ueno Y, Miyazawa Y, Kurata H, Deguchi T, Watanabe N, Takagi T, Wakimoto S, Okuyama R, Abe M, Kurikawa N, Kawamura S, Yamato M, Osumi J.
Bioorg Med Chem Lett., 19, 15, 4151-4158, 2009
In vivo antisense activity of ENA oligonucleotides targeting PTP1B mRNA in comparison of that of 2'-MOE-modified oligonucleotides
Koizumi M, Takagi-Sato M, Okuyama R, Araki K, Sun W, Nakai D.
Nucleic Acids Symp Ser (Oxf)., 51, 111-112, 2007
Direct comparison of in vivo antisense activity of ENAregistered oligonucleotides targeting PTP1B mRNA with that of 2'-MOE-modified oligonucleotides
Koizumi M, Takagi-Sato M, Okuyama R, Araki K, Sun W-Y, Nakai D, Tsutsumi S, Kawai K.
Oligonucleotides, 16, 253-262, 2006
Turnover and Characterization of UDP-N-Acetylglucosaminyl Transferase (OGT) in a Stably Transfected HeLa Cell Line
Marshall S, Okuyama R, Rumberger JM.
Biochem. Biophys. Res. Commun., 332, 1, 263-270, 2005
Identification of molecular target of AMP-activated protein kinase activator by affinity purification and mass spectrometry
Kosaka T*, Okuyama R*, Sun W-Y, Ogata T, Harada J, Araki K, Izumi M, Yoshida T, Okuno A, Fujiwara T, Ohsumi J, Ichikawa K.
Anal. Chem., 77, 7, 2050-2055, 2005
Glucosamine Induces Rapid Desensitization of Glucose Transport in Isolated Adipocytes by Increasing GlcN-6-P Levels
Marshall S, Yamasaki K, Okuyama R.
Biochem. Biophys. Res. Commun., 329, 3, 1155-1161, 2005
Potential Regulation of Nuclear UDP-N-acetylglucosaminyl Transferase (OGT) by Substrate Availability : Ability of Chromatin Protein to Bind UDP-N-acetylglucosamine and Reduce OGT-mediated O-linked Glycosylation
Okuyama R, Marshall S.
Biol. Pham. Bull., 27, 8, 1293-1296, 2004
Differential Effects of Vanadate on UDP-N-Acetylglucosaminyl Transferase (OGT) Activity Derived from Cytosol and Nucleosol
Marshall S, Okuyama R.
Biochem. Biophys. Res. Commun., 318, 4, 911-915, 2004
UDP-N-acetylglucosaminyl Transferase (OGT) in Brain Tissue: Temperature Sensitivity and Subcellular Distribution of Cytosolic and Nuclear Enzyme
Okuyama R, Marshall S.
J. Neurochem., 86, 5, 1271-1280, 2003
High Glucose Potentiates Palmitate-induced NO-mediated Cytotoxicity through Generation of Superoxide in Clonal Beta-cell HIT-T15
Okuyama R, Fujiwara T, Ohsumi J.
FEBS Lett., 545, 2-3, 219-223, 2003
Measurement of UDP-N-Acetylglucosaminyl Transferase (OGT) in Brain Cytosol and Characterization of Anti-OGT Antibodies
Marshall S, Duong T, Orbus RJ, Rumberger JM, and Okuyama R.
Anal. Biochem., 314, 2, 169-179, 2003
Cytosolic O-GlcNAc Accumulation is not Involved in Beta-cell Death in HIT-T15 or Min6
Okuyama R, Yachi M.
Biochem. Biophys. Res. Commun., 287, 2, 366-371, 2001
Differential Potentiation by Depolarization of the Effects of Calcium Antagonists on Contraction and Ca2+ Current in Guinea-pig Heart
Okuyama R, Adachi-Akahane S, Nagao T.
Br. J. Pharmacol., 113, 2, 451-456, 1994
Quaternary Diltiazem Can Act from Both Sides of the Membrane in Ventricular Myocytes
Adachi-Akahane S, Amano Y, Okuyama R, Nagao T
Jpn. J. Pharmacol., 61, 3, 263-266, 1993